Clinical and virological outcomes of TB/HIV co-infected patients treated with dolutegravir-based HIV antiretroviral regimens: Programmatic experience from Botswana

Background:Dolutegravir (DTG) has recently been recommended as a preferred first-line regimen for the treatment of new and treatment-experienced HIV-infected patients. However, potential drug interactions between DTG and rifampicin remain a clinical and public health concern.Methods:We analyzed HIV